Aktana Status
The company raised $21.07 million of Series C venture funding from undisclosed investors on September 26, 2018, putting the company's pre-money valuation at $93.62 million.
Developer of a decision support platform that synthesizes and prioritizes data to provide commercial teams relevant insights and suggested actions within their workflows. The company's platform harnesses machine learning algorithms, analyzes market data, channel activity and HCP preference in real-time, enabling pharmaceutical companies to increase revenue, capitalize on data investments, and drive channel productivity and results.
Generating Revenue
Privately Held (backing)
Venture Capital-Backed
Scaling your AI programs can be a challenging task. We've identified the 3 steps you need to take to facilitate wide-scale adoption – prioritizing data & integrations, recognizing common components and finally, identifying what needs to be localized. https://t.co/b15PFMLvCo https://t.co/PEGR6fUD8N
Is your organization striving to close the loop between your sales and marketing teams? Our latest blog by Aktana's Toni Cejas explores how a flexible system-design approach, coupled with the right technology, can help you achieve just that. Read it here: https://t.co/4E8eMJp4eL
Come and see us in London tomorrow at The Pharma Multi-Channel Excellence Conference. We’re joining industry experts to discuss how to stay ahead of the game with channel capabilities that adapt to the ever-evolving demands of HCPs, patients and customers. https://t.co/bun3m399EF https://t.co/z6IlIQF6Kj
You don't need perfect data to create impactful business opportunities from #AI. Our latest blog, with real-life perspective from @genentech, outlines 8 ways you can achieve quick wins with the data you have by adopting an AI-driven commercial strategy. https://t.co/xT2SdIuJsa
The company raised $21.07 million of Series C venture funding from undisclosed investors on September 26, 2018, putting the company's pre-money valuation at $93.62 million.
Scaling your AI programs can be a challenging task. We've identified the 3 steps you need to take to facilitate wide-scale adoption – prioritizing data & integrations, recognizing common components and finally, identifying what needs to be localized. https://t.co/b15PFMLvCo https://t.co/PEGR6fUD8N
Is your organization striving to close the loop between your sales and marketing teams? Our latest blog by Aktana's Toni Cejas explores how a flexible system-design approach, coupled with the right technology, can help you achieve just that. Read it here: https://t.co/4E8eMJp4eL
Come and see us in London tomorrow at The Pharma Multi-Channel Excellence Conference. We’re joining industry experts to discuss how to stay ahead of the game with channel capabilities that adapt to the ever-evolving demands of HCPs, patients and customers. https://t.co/bun3m399EF https://t.co/z6IlIQF6Kj
You don't need perfect data to create impactful business opportunities from #AI. Our latest blog, with real-life perspective from @genentech, outlines 8 ways you can achieve quick wins with the data you have by adopting an AI-driven commercial strategy. https://t.co/xT2SdIuJsa
Being your true self, unapologetically and without fear, is the purest form of celebration. This month and always, here’s to cultivating joy and inclusivity by honoring the differences that make our humanity whole. From our Aktana community to yours, happy #PRIDE! https://t.co/lqU1GovFMN
In case you missed it, Erasmus Holm at MSD spoke with Aktana’s Jonny Rawlinson about the common challenges faced when building commercial ecosystems and what AI’s role looks like in a commercial strategy - now and in the future. Watch their session here: https://t.co/VvbfnPIluJ https://t.co/iYUfnIzL04
''Today, AI is for all.'' Aktana's Alan Kalton explores how AI is now impacting the #medicaldevice industry and why breaking down barriers to adoption is crucial to enhancing business operations moving forward. Read the full article here. https://t.co/fzvanHb01w
On this special episode of our podcast, industry leaders from Biogen, Genentech and Novartis draw from their firsthand experience deploying AI programs to share lessons learned in a roundtable discussion from our recent Masterclass. Listen to it here! https://t.co/Co1QCt8nAx https://t.co/Ayd5qaNQrC
“We’re providing our sales team with the cutting-edge tools needed in today’s market to help them be successful.” @endpts shares results from @almirall's recent deployment of #ContextualIntelligence, which has cut pre-call planning from hours to minutes: https://t.co/HZHN5AJJws
Miss the last episode of #ContextualIntelligence? Catch up with key takeaways from Ep. 15 featuring @genentech's Youssef Idelcaid, who shares the lean startup approach he’s using to shape the #datascience strategy for one of the world’s leading #biotechs: https://t.co/jVXy1zVqzv https://t.co/H3w0x0jHjl
Most visits will take between 1.5 and 2 hours. The agenda for a specific visit depends on your group, its interests and objectives as well as on the host company. A visit may include a company or industry specific presentation, a discussion around a specific product or service, partnership opportunities, a demo, a meeting of the premises, etc.
Add a review